Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions

Journal of Clinical Pharmacy and Therapeutics

Volumn 26, Issue 2, 2001, Pages 155-156

  Brunstein, M G ^a   Belmonte de Abreu, P ^a   Souza, D O ^b   Lara, Diogo R ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; DIPYRIDAMOLE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; HALOPERIDOL;

DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; HUMAN; LETTER; RECEPTOR BLOCKING; SCHIZOPHRENIA;

ADENOSINE; DIPYRIDAMOLE; GLUTAMIC ACID; HUMANS; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 0035061620     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2001.00335.x     Document Type: Letter

References (18)

1. Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions
2. Schizophrenia: A purinergic hypothesis
3. Adenosine A2A agonists: A potential new type of atypical antipsychotic
4. Relationship between dopamine D2 occupancy, clinical response, and side effects: A doubleblind PET study of first-episode schizophrenia
5. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - A double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist
6. Role of adenosine as a modulator of synaptic activity in the central nervous system
7. Selective adenosine A2a receptor/dopamine D2 receptor interactions in animal models of schizophrenia
8. Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor' agonists
9. Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats
10. Purine modulation of dizocilpine effects on spontaneous alternation
11. Evaluation of antagonists of the discriminative stimulus and response rate effects of phencyclidine
12. The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat
13. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine
14. Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: Implications for the PCP model of schizophrenia
15. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitve disruptions associated with the prefrontal cortex
16. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
17. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine
18. Adenosine uptake sites in brain: Regional distribution of putative subtypes in relationship to adenosine A1-receptors